It would be very beneficial to request a chronic kidney disease screening in patients with diabetes in its earliest stages, staging according to the KDIGO Guidelines, and the appropriate use of SGLT2 inhibitors and other nephroprotective drugs when indicated. Here, SLC5A2 is linked to chronic kidney disease.